Innovative Medicine

Phase 3 ANDROMEDA study investigated the first and only subcutaneous anti-CD38 monoclonal antibody in treatment of rare multi-system disease with a high unmet medical need andfor which there are currently no approved therapies Data selected as late-breaking abstract and featured in press briefing at European Hematology Association (EHA) Annual Congress

The investigational Ebola vaccine regimen leverages Janssen’s established AdVac® and PER.C6® technologies and Bavarian Nordic’s MVA-BN® technology The AdVac® and PER.C6® technologies have been used to construct Janssen’s COVID-19, Zika, Respiratory Syncytial Virus (RSV) and HIV vaccine candidates

Longer-term follow-up data from Phase 1b/2 CARTITUDE-1 study demonstrate 100% overall response rate, 86% stringent complete response rate at a median of 11.5 months and 86% progression-free survival at 9 months

Submissions demonstrate Janssen’s commitment to developing new options for young patients

South Africa’s Rugby World Cup Winning Captain Siya Kolisi kickstarts behavior change efforts “For Humankind”; calls on other stars from sports and screen to continue to rally around protective actions, like #MaskingForAFriend

Patients ages 70 years or younger who were new to CLL treatment lived longer without disease progression with the IMBRUVICA®-based regimen compared to patients treated with a chemoimmunotherapy regimen